Cáncer Renal segunda línea - page 20

Plimack E et al. KCS 2016
Response Rate with Nivolumab in mRCC
1...,10,11,12,13,14,15,16,17,18,19 21,22,23,24,25,26,27,28,29,30,...35
Powered by FlippingBook